Literature DB >> 15020498

Acute coronary syndromes: should women receive less antithrombotic medication than men?

N Danchin1.   

Abstract

A recent meta-analysis of all randomised trials assessing the efficacy and safety of glycoprotein IIb/IIIa agents with acute coronary syndromes showed that there was a significant interaction with sex. Explaining this difference requires an analysis of whether it has any pathophysiological basis, whether antithrombotic medications are indeed less efficacious in women in different clinical situations, and whether there are any specific reasons that may have led to the provocative results of the meta-analysis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15020498      PMCID： PMC1768185          DOI： 10.1136/hrt.2002.003483

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  23 in total

1.  Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.

Authors:  L Cho; E J Topol; C Balog; J M Foody; J E Booth; C Cabot; N S Kleiman; J E Tcheng; R Califf; A M Lincoff
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.

Authors:  Ioannis Iakovou; George Dangas; Roxana Mehran; Alexandra J Lansky; Yoshio Kobayashi; Milena Adamian; Sotir Polena; Micheal B Collins; Gary S Roubin; Gregg W Stone; Martin B Leon; Jeffrey W Moses
Journal:  Am J Cardiol       Date:  2002-04-15       Impact factor: 2.778

3.  Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory).

Authors:  B L Sharaf; C J Pepine; R A Kerensky; S E Reis; N Reichek; W J Rogers; G Sopko; S F Kelsey; R Holubkov; M Olson; N J Miele; D O Williams; C N Merz
Journal:  Am J Cardiol       Date:  2001-04-15       Impact factor: 2.778

4.  Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.

Authors:  B E Tardiff; L K Jennings; R A Harrington; D Gretler; R F Potthoff; D A Vorchheimer; P R Eisenberg; A M Lincoff; M Labinaz; D M Joseph; M F McDougal; N S Kleiman
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

5.  Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

Authors:  A M Lincoff; R A Harrington; R M Califf; J S Hochman; A D Guerci; E M Ohman; C J Pepine; S L Kopecky; N S Kleiman; C M Pacchiana; L G Berdan; M M Kitt; M L Simoons; E J Topol
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

6.  Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.

Authors:  B Lagerqvist; K Säfström; E Ståhle; L Wallentin; E Swahn
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

7.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

Authors:  Eric Boersma; Robert A Harrington; David J Moliterno; Harvey White; Pierre Théroux; Frans Van de Werf; Anneke de Torbal; Paul W Armstrong; Lars C Wallentin; Robert G Wilcox; John Simes; Robert M Califf; Eric J Topol; Maarten L Simoons
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

8.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

9.  Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.

Authors:  Richard C Becker; Frederick A Spencer; Michael Gibson; Janet E Rush; Gerard Sanderink; Sabina A Murphy; Steven P Ball; Elliott M Antman
Journal:  Am Heart J       Date:  2002-05       Impact factor: 4.749

10.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690
View more
  1 in total

1.  Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study.

Authors:  Leslie Cho; Byron Hoogwerf; Julie Huang; Danielle M Brennan; Stanley L Hazen
Journal:  J Womens Health (Larchmt)       Date:  2008-05       Impact factor: 2.681
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.